Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 12/20 | 0.57 |
| ▸ | CTSD | P07339 | 1/20 | 0.53 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | NPY1R | P25929 | 1/20 | 0.48 |
| ▸ | NPY2R | P49146 | 1/20 | 0.48 |
| ▸ | NPY4R | P50391 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30799638 | 0.94 | MMP2 (0.56) | BACE1MMP2OPRK1NPY1RNPY2R | |
| SCHEMBL30609958 | 0.93 | BACE1 (0.51) | BACE1CTSDMMP2OPRK1 | |
| SCHEMBL30609969 | 0.93 | BACE1 (0.51) | BACE1CTSDMMP2OPRK1 | |
| SCHEMBL30799335 | 0.93 | MMP2 (0.55) | BACE1CTSDMMP2OPRK1NPY1R | |
| SCHEMBL31181232 | 0.92 | BACE1 (0.53) | BACE1CTSDOPRK1 | |
| SCHEMBL29798061 | 0.91 | NPY4R (0.58) | BACE1CTSDOPRK1NPY1RNPY2R | |
| SCHEMBL30799561 | 0.91 | BACE1 (0.54) | BACE1CTSDMMP2OPRK1 | |
| SCHEMBL30497073 | 0.91 | MMP2 (0.56) | BACE1MMP2OPRK1NPY1RNPY2R | |
| SCHEMBL31554972 | 0.91 | MMP2 (0.56) | BACE1MMP2OPRK1NPY1RNPY2R | |
| SCHEMBL30688844 | 0.91 | MMP2 (0.55) | BACE1CTSDMMP2OPRK1NPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116985-A1 | STAPLED PEPTIDES AND METHODS THEREOF | PARABILIS MEDICINES, INC. | 2024-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116985-A1 | STAPLED PEPTIDES AND METHODS THEREOF | CTNNB1, APC, CTNNA1 | BACE1 10/4885CTSD 2704/4885MMP2 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.